2022 Azilect (Parkinson’s Disease) - Forecast and Market Analysis

1
Azilect (Parkinsons Disease) Forecast and
Market Analysis to 2022
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_marketoptimizer.org with
your contact details and questions if any.

• Published Mar 2014
• Single User PDF US 3495
• Corporate User PDF US 10485

2
Azilect (Parkinsons Disease) Forecast and
Market Analysis to 2022

• Parkinsons disease is a progressive condition
  that is characterized by bradykinesia, muscular
  rigidity, tremor, and postural instability. As
  the second most common neurodegenerative
  disorder, Parkinsons disease may affect
  individuals of any age but prevalence is
  increased with age and it is most common in the
  elderly. Dopaminergic therapies have been fairly
  effective in treating bradykinesia, but several
  unmet needs remain. Some needs will be met during
  the forecast period from 2012-2022, while others,
  such as the need for disease-modifying drugs,
  will remain.
• Researcher expects that advancements will be made
  in levodopa administration and that four new
  molecular entities will be introduced to the
  market by 2022, these factors along with
  increased patient numbers from an aging
  population will drive the market during the
  forecast period.
• Inquire about this report at http//www.marketopti
  mizer.org/contacts/purchase?rname5923

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
3
Azilect (Parkinsons Disease) Forecast and
Market Analysis to 2022

• Azilect (rasagiline) is a second-generation MAO-B
  inhibitor, developed by Teva Pharmaceuticals for
  the treatment of the signs and symptoms of
  Parkinsons disease. Azilect is approved for use
  as a monotherapy in early Parkinsons disease at
  a once-daily dosage of 1mg, or as an adjunctive
  therapy to levodopa at 0.5mg or 1mg, as needed,
  once daily (Azilect package insert, 2012).
• Scope
• Overview of Parkinsons disease, including
  epidemiology, etiology, symptoms, diagnosis,
  pathology and treatment guidelines as well as an
  overview on the competitive landscape.
• Detailed information on Azilect including product
  description, safety and efficacy profiles as well
  as a SWOT analysis.
• Sales forecast for Azilect for the top seven
  countries from 2012 to 2022.

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
4
Azilect (Parkinsons Disease) Forecast and
Market Analysis to 2022

• Reasons to buy
• Understand and capitalize by identifying products
  that are most likely to ensure a robust return
• Stay ahead of the competition by understanding
  the changing competitive landscape for
  Parkinsons disease
• Effectively plan your MA and partnership
  strategies by identifying drugs with the most
  promising sales potential
• Make more informed business decisions from
  insightful and in-depth analysis of Azilect
  performance
• Obtain sales forecast for Azilect from 2012-2022
  in the top seven countries (the US, France,
  Germany, Italy, Spain, the UK and Brazil).
• Get a detailed report at http//www.marketoptimiz
  er.org/azilect-parkinsons-disease-forecast-and-mar
  ket-analysis-to-2022.html .

Call Now 1 888 391 5441 Email at
sales_at_marketoptimizer.org
5
Azilect (Parkinsons Disease) Forecast and
Market Analysis to 2022

• About Us
• marketoptimizer.org is an online market research
  reports library of 250,000 in-depth studies of
  over 5000 micro markets. Our database includes
  reports by leading publishers from across the
  globe. We provide 24/7 online and offline support
  service to our customers. marketoptimizer.org
  also offers company data, country profiles,
  trends, information and analysis on the sector of
  your interest.
• Visit Us _at_
• http//www.marketoptimizer.org
• Follow Us

Call Now 1 888 391 5441 Email sales _at_
sales_at_marketoptimizer.org